PFE

Pfizer Stock Defies Yearly Trends, Soars Today

Pfizer stock is trading -19.75% below its average target price of $32.66 after marking a 1.5% during today's afternoon session. Analysts are giving the Large-Cap Pharmaceutical company an average rating of buy and target prices ranging from $25.0 to $45.0 per share.

The stock has a very low short interest at 1.7%, and a short ratio of 2.07. At 0.05%, the company's rate of insider ownership does not indicate that management is heavily invested in the corporation. Finally, we also note that an average number of institutional investors are invested in the stock, with 67.8% of Pfizer's shares being owned by this investor type.

Institutions Invested in Pfizer

Date Reported Holder Percentage Shares Value
2024-09-30 Vanguard Group Inc 9% 516,249,875 $13,530,908,751
2024-09-30 Blackrock Inc. 8% 436,001,294 $11,427,593,516
2024-09-30 State Street Corporation 5% 290,460,600 $7,612,972,060
2024-09-30 Wellington Management Group, LLP 3% 163,727,320 $4,291,292,907
2024-09-30 Charles Schwab Investment Management, Inc. 2% 130,143,942 $3,411,072,600
2024-09-30 Geode Capital Management, LLC 2% 117,666,245 $3,084,032,173
2024-06-30 Norges Bank Investment Management 1% 83,963,188 $2,200,675,080
2024-09-30 Morgan Stanley 1% 77,971,216 $2,043,625,499
2024-09-30 Massachusetts Financial Services Co. 1% 71,151,857 $1,864,890,106
2024-09-30 State Farm Mutual Automobile Insurance Co 1% 54,508,560 $1,428,669,307

Besides an analyst consensus of some upside potential, other market factors point to there being mixed market sentiment on Pfizer.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS